Merck & Co., Inc. (MRK) Operating Cash Flow CAGR:N/A(TTM)
The operating cash flow cagr for Merck & Co., Inc. (MRK) is N/A over the latest trailing 12-month period. Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
The operating cash flow cagr for Merck & Co., Inc. (MRK) stock is N/A over the past 12 months. The 3 year average growth rate is 4.51% and the 5 year cagr is 9.55%. Operating cash flow CAGR measures the compound annual growth rate of the cash Merck & Co., Inc. generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history. The 1-year (TTM) figure is omitted: a one-year rate off a single quarter's base is volatile; the multi-year figures are the reliable read.
MRK Operating Cash Flow CAGR Chart
Merck & Co., Inc. (MRK)
MRK Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $21.47B | $16.47B | $-5.00B | -23.27% | -23.27% |
| 2024 | $13.01B | $21.47B | +$8.46B | +65.06% | +65.06% |
| 2023 | $19.09B | $13.01B | $-6.09B | -31.89% | -31.89% |
| 2022 | $14.11B | $19.09B | +$4.99B | +35.34% | +35.34% |
| 2021 | $10.25B | $14.11B | +$3.86B | +37.61% | +37.61% |
| 2020 | $13.44B | $10.25B | $-3.19B | -23.71% | -23.71% |
| 2019 | $10.92B | $13.44B | +$2.52B | +23.05% | +23.05% |
| 2018 | $6.45B | $10.92B | +$4.47B | +69.41% | +69.41% |
| 2017 | $10.38B | $6.45B | $-3.93B | -37.87% | -37.87% |
| 2016 | $12.42B | $10.38B | $-2.04B | -16.46% | -16.46% |
| 2015 | $7.86B | $12.42B | +$4.56B | +58.03% | +58.03% |
| 2014 | $11.65B | $7.86B | $-3.79B | -32.56% | -32.56% |
| 2013 | $10.02B | $11.65B | +$1.63B | +16.28% | +16.28% |
| 2012 | $12.38B | $10.02B | $-2.36B | -19.07% | -19.07% |
| 2011 | $10.82B | $12.38B | +$1.56B | +14.42% | +14.42% |
| 2010 | $3.39B | $10.82B | +$7.43B | +219.04% | +219.04% |
| 2009 | $6.57B | $3.39B | $-3.18B | -48.38% | -48.38% |
| 2008 | $7.00B | $6.57B | $-427.50M | -6.11% | -6.11% |
| 2007 | $6.77B | $7.00B | +$234.00M | +3.46% | +3.46% |
| 2006 | $7.61B | $6.77B | $-843.30M | -11.08% | -11.08% |
| 2005 | $8.80B | $7.61B | $-1.19B | -13.53% | -13.53% |
| 2004 | $9.86B | $8.80B | $-1.06B | -10.78% | -10.78% |
| 2003 | $9.53B | $9.86B | +$333.70M | +3.50% | +3.50% |
| 2002 | $9.08B | $9.53B | +$448.80M | +4.94% | +4.94% |
| 2001 | $7.69B | $9.08B | +$1.39B | +18.12% | +18.12% |
| 2000 | $6.13B | $7.69B | +$1.56B | +25.39% | +25.39% |
| 1999 | $5.33B | $6.13B | +$802.40M | +15.06% | +15.06% |
| 1998 | $6.32B | $5.33B | $-988.30M | -15.65% | -15.65% |
| 1997 | $5.43B | $6.32B | +$888.90M | +16.38% | +16.38% |
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis